Basic Information
| LncRNA/CircRNA Name | H19 |
| Synonyms | H19, ASM, ASM1, BWS, D11S813E, LINC00008, NCRNA00008, WT2 |
| Region | GRCh38_11:1995176-2001470 |
| Ensemble | ENSG00000130600 |
| Refseq | NR_002196 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Western blot, other |
| Sample | PCa tissues and cell lines (C27IM, C38IM) |
| Expression Pattern | down-regulated |
| Function Description | We found that combined treatment caused a significant H19 down-regulation as compared with hypoxia. In turn, H19 acts as a transcriptional repressor of cell adhesion molecules, as revealed by up-regulation of both ?3 and ?4 integrins and E-cadherin upon H19 silencing or combined treatment. Importantly, H19 down-regulation and ? integrins induction were also observed in treated OSCs. Combined treatment increased both cell motility and invasion of PCa cells. Lastly, reduction of ? integrins and invasion was achieved through epigenetic modulation of H19-dependent transcription. |
| Pubmed ID | 31426484 |
| Year | 2019 |
| Title | H19-Dependent Transcriptional Regulation of ?3 and ?4 Integrins Upon Estrogen and Hypoxia Favors Metastatic Potential in Prostate Cancer |
External Links
| Links for H19 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |